Jubilant Life Sciences Ltd. Stock Info: As on 2018-05-24 15:56:20
|Market Cap / Sales Ratio||5.11|
|Basic EPS (Rs.)||4.97|
|Return On Assets||1.80|
|Parameter||Mar-17 (₹ Cr.)||Yoy%change|
|Total share capital||15.93|
|Parameter||Mar-17 (₹ Cr.)||6M % change|
|Total share capital||15.93|
|Company||Curr Price||Prev. Close||Change%||W's Low/High|
Aarti Drugs Ltd.
Abbott India Ltd.
Ajanta Pharma Ltd.
Albert David Ltd.
Alembic Pharmaceuticals Ltd.
Alkem Laboratories Ltd.
|Company||Curr Price||Prev. Close||Change%||W's Low/High|
Aarey Drugs & Pharmaceuticals Ltd.
Aarti Drugs Ltd.
Aayush Food & Herbs Ltd.
Abbott India Ltd.
ABL Bio-Technologies Ltd.
Addlife Pharma Ltd.
Adinath Bio-Labs Ltd.
|Parameter||Mar-17(in ₹ Cr.)|
|Cash from operating activities||419.15|
|Cash from investing activities||-43.07|
|Cash from financing activities||-338.40|
|Net change in cash||37.69|
Stock Held By Mutual Fund Schemes
|Motilal Oswal Multicap 35 Fund||3.44%|
|Canara Robeco Emerging Equities||1.91%|
|DSP BlackRock Equity Opportunities Fund||1.09%|
|Motilal Oswal Dynamic Fund||2.54%|
|Motilal Oswal Long Term Equity Fund||3.26%|
|Canara Robeco Equity Tax Saver||1.82%|
M Venkatesh appointed MRPL MD
M Venkatesh has been appointed as the Managing Director of Mangalore Refineries and Petrochemicals Limited (MRPL), an order issued by the Personnel Ministry said today. Vekatesh is at present Director (Refineries) in the MRPL, a subsidiary of the Oil and Natural Gas Corporation Limited (ONGC) He has been appointed to the post for a period of five years with effect from the date of his assumption of charge of the post on or after June 1, 2018, or till the date of his superannuation, the order said.
TCS expands operations in Florida as part of Transamerica deal
India's largest IT services firm TCS today said it has expanded operations in Florida, US, with over 430 employees joining the company as part of its deal with Transamerica. In January, Tata Consultancy Services (TCS) had signed an over USD 2 billion deal with Transamerica to administer the latter's life insurance, annuity, supplemental health insurance, and workplace voluntary benefits products. It covered managing administration of more than 10 million policies. More than 430 former Transamerica employees now work for TCS at this new St Petersburg facility (in Florida) as part of recruiting and investing in more than 2,200 Transamerica jobs across the US in multiple locations, the Indian software services giant said in a statement. TCS will occupy several floors of Transamerica's building at 570 Carillon Parkway in St Petersburg, as part of a multi-year agreement with Transamerica... The St Petersburg office is a new US business centre for TCS, adding to the over 1,000 employees already serving American businesses throughout the state, it added. TCS said it has invested nearly USD 3 billion in the US over the past three years and has been among the top two IT services job creators in the country. TCS is a leading industry employer in the US, striving to help American companies like Transamerica to digitally transform their business and capitalise on rapidly evolving customer demands, TCS President and Global Head (Banking, Financial Services and Insurance Platforms) Suresh Muthuswami said. We look forward to partnering with St Petersburg's city, state and local organizations to further build upon our business and community impact, he added. The company said it has made tremendous community impact in Florida over past several years.
Kotak India Growth Fund Series 4 - Direct Plan: change in investment factsheets for April
Kotak India Growth Fund Series 4 - Direct Plan has announced change in investment factsheets and fund flash for the month ended April 30, 2018. As on Apr 30, 2018, the total size of the Fund was Rs 429.99 crores, compared with Rs 424.96 crores in the last month. The Fund's NAV per unit was Rs 9.89 for Growth, while 52-Week High and Low ranges were Rs 10.35 and Rs 9.51 respectively. The Equity - Diversified fund with Growth plan was launched on Jan 29, 2018 and managed by Fund Managers Harsha Upadhyaya, Devender Singhal. The top five companies based on a percentage of total holdings were ITC Ltd. (35.18 Cr.), HDFC Bank Ltd. (19.44 Cr.), Mahindra & Mahindra Ltd. (19.21 Cr.), Tata Motors Ltd. (17.02 Cr.) and Bata India Ltd. (16.05 Cr.). Kotak India Growth Fund Series 4 - Direct Plan is promoted by Kotak Mahindra Mutual Fund and managed by Kotak Mahindra Asset Management Company Ltd..
Kotak India Growth Fund Series 4: change in investment factsheets for April
Kotak India Growth Fund Series 4 has announced change in investment factsheets and fund flash for the month ended April 30, 2018. As on Apr 30, 2018, the total size of the Fund was Rs 429.99 crores, compared with Rs 424.96 crores in the last month. The Fund's NAV per unit was Rs 9.88 for Growth, while 52-Week High and Low ranges were Rs 10.34 and Rs 9.51 respectively. The Equity - Diversified fund with Growth plan was launched on Jan 29, 2018 and managed by Fund Managers Harsha Upadhyaya, Devender Singhal. The top five companies based on a percentage of total holdings were ITC Ltd. (35.18 Cr.), HDFC Bank Ltd. (19.44 Cr.), Mahindra & Mahindra Ltd. (19.21 Cr.), Tata Motors Ltd. (17.02 Cr.) and Bata India Ltd. (16.05 Cr.). Kotak India Growth Fund Series 4 is promoted by Kotak Mahindra Mutual Fund and managed by Kotak Mahindra Asset Management Company Ltd..
BLS International to assist Sopra Steria on UK visa renewals
Visa service provider BLS International today said theUnited Kingdom Visas and Immigration (UKVI) has awarded Sopra Steria a new contract to enable visa renewals for those individuals who are already in the UK. BLS International will support Sopra Steria and UKVI, a division of the UK Home Office responsible for deciding who can visit and stay within the UK, by establishing and delivering some of the key add value services under the contract, it said in a release. BLS International claims to handle about 12 million visa applications annually across the globe at present. Meanwhile, shares of the company were trading at Rs 172.55 apiece, up 1 per cent from the previous close at 10:50 hours on BSE.
Jubilant Life gets USFDA nod for Niacin extended release tablets
Jubilant Life Sciences Ltd today said it has received the final approval from USFDA for its generic Niacin extended-release tablets used for controlling cholesterol levels. The approval granted by the US Food and Drug Administration (USFDA) to the company's wholly-owned arm Jubilant Pharma Ltd, is for multiple strengths of Niacin extended-release tablets of 500 mg, 750 mg, and 1,000 mg, the company said in a statement. These are the generic equivalent of AbbVie's Niaspan, which is indicated to reduce elevated high-density lipoprotein (known as bad cholesterol), among others while increasing HDL-C (good cholesterol) in patients with primary hyperlipidemia and mixed dyslipidemia. The drug helps reduce the risk of recurrent nonfatal myocardial infarction (heart attack) in patients with a history heart disease and hyperlipidemia, the statement added. This is the first approval that we have received from the USFDA during the current financial year, it said. As on March 31, 2018, Jubilant had a total of 94 ANDAs for oral solids filed in the US, the company said.
Jubilant Life Scienc - Updates
Jubilant Life Sciences Limited has informed the Exchange regarding ''Jubilant receives ANDA approval for Niacin Extended-Release Tablets USPNoida''.
Jubilant Life Scienc - USFDA Approval
We enclose a communication pertaining to USFDA approval.
Jubilant Life Scienc Q4 net profit zooms 234.46% at Rs 86.39 cr
The company reported standalone net profit of Rs 86.39 crore for the quarter ended March 31, 2018 as compared to Rs 25.83 crore in the same period last year, registering a year-on-year growth of 234.46 per cent. Net revenue of the company rose substantially by 34.69 per cent at Rs 951.64 crore in January-March quarter of this fiscal as against Rs 706.54 crore in the corresponding period last year. During January-March quarter, operating expenses increased by 25.31 per cent to Rs 800.03 crore from Rs 638.45 crore in year ago period. Other Income dipped by 21.65 per cent at Rs 7.89 crore versus (Mar'17 Rs 10.07 crore). Operating Profit surged by 98.29 per cent to Rs 164.40 crore as against Rs 82.91 crore in the year ago period, while Operating Profit Margin (OPM) expanded year-on-year to 47.31 per cent in March quarter. Interest declined by 23.53 per cent y-o-y to Rs 32.75 crore, while Taxation increased by 618.18 per cent at Rs 32.39 crore (Mar'17 Rs 4.51 crore).
Jubilant Life Scienc - Updates
Jubilant Life Sciences Limited has informed the Exchange regarding ''Issuance of Commercial Papers of Rs. 80 crore''.
Jubilant Life Scienc - USFDA Approval
We enclose a communication pertaining to USFDA approval.
Jubilant Life Scienc - Announcement under Regulation 30 (LODR)-Newspaper Publication
In continuation of our letter dated May 9, 2018, we enclose copies of the Audited Consolidated Financial Results for the quarter and year ended March 31, 2018 published on May 10, 2018 in MINT (English) and HINDUSTAN (Hindi).
Jubilant Life Scienc - Issuance Of Commercial Papers Of Rs. 80 Crore
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company has issued Commercial Papers ('CPs') of Rs. 80 crore on May 10, 2018.
YEAR EVENTS 1978 - The Company was incorporated on 21st June, in Uttar Pradesh. The Company manufacture Vinyl Acetate Monomer (VAM). The Company was promoted by A.B. Bofors (Swedish Multinational), Hindustan Wires Ltd., and Mr. M.L. Bhartia. - The Company entered into a technical collaboration agreement with Noble Chematur Division of A.B. Bofors, Sweden for the supply of know-how and basic engineering for the manufacture of vinyl acetate monomer. 1981 - 1,200 No. of equity shares subscribed for by the signatories to the Memorandum of Association. 34,63,800 No. of equity and 38,500 Pref. shares issued through a prospectus during Mar./Apr. 1982, 19,250 Pref. shares each reserved and allotted to UPSIDC and PICUP. 6,08,370 No. of equity shares reserved and allotted to Indian private promoters and their associates, 6,55,430 No. of equity shares reserved and allotted to AB Brothers of Sweden and 22,00,000 No. of equity shares offered at par for public subscription. Pref. shares redeemable during 28.5.1993/96. 1982 - 6,93,000 Rights Equity shares issued at par in prop. 1:5 (only 5,52,043 shares taken up). The remaining 1,40,357 shares allotted on private placement basis (including 96,800 shares to non-residents). 1983 - Another technical collaboration agreement was signed with Crown Decorative Products Ltd., U.K., and Reed International Company for the manufacture of high pressure emulsions i.e., Polyvinyl Acetate Emulsions. This project was commissioned in 1985-86. - During November, the Company promoted `India Glycols Ltd.' to take up the implementation of a project to manufacture Mono Ethylene Glyco (MEG) at Kashipur, U.P., in technical collaboration with Scientific Design Co. Int., U.S.A. Commercial production commenced on 1st January, 1990. 1984 - A technical collaboration agreement was signed with Technimont Spa of Italy for the manufacture of polyvinyl alcohol with an installed capacity of 2,000 tonnes per annum. The unit was commissioned in July 1991, with an installed capacity of 650 MT per annum. During 1991, the capacity was doubled to 1,400 tonnes per annum. The Company proposed to enhance the capacity of 2,000 MT per annum by installing additional equipment. 1985 - Vam Leasing Ltd., and Vam Investments Ltd., were incorporated as wholly owned subsidiaries of the Company. 1986 - 10,06,180 No. of equity shares issued at par to financial institutions on conversion of loans. 1987 - The Company decided to set up a plant to recover carbon dioxide in collaboration with Hydrogas Denmart a.s. of Denmark and manufacture to dry ice. The plant was commissioned in 1989. A biogas plant was also set up in collaboration with Biotim N.V. of Belgium as a part of energy conservation programme. - The Company also promoted `Insilco Ltd.' jointly with Degussa AG of West Germany for the manufacture of spray dried silica. The project was expected to go on stream by the middle of 1991. - Applications were also submitted to Government for increasing the production capacity of vinyl acetate monomer from 10,000 tonnes to 20,000 tonnes per annum. - In order to part finance the vinyl acetate monomer project, during January, the company privately placed with financial institutions, 15% non-convertible debentures worth Rs 1.00 crores. These debentures are redeemable at a premium of 5% in three equal annual instalments commencing on 27th April, 1993. - The Company privately placed with financial institutions 14% non-convertible debentures worth Rs 1.50 crores. These debentures are redeemable in full at a premium of 5% on 29th December, 1994. 1989 - A synthetic wood adhesive "Vamicol" was launched in January and liquid and dry carbon-di-oxide (dryice) were launched in March. The company installed another new boiler of capacity 25 tonnes steam/hour based on the fluidised bed technology to eliminate air pollution. - The Company privately placed with financial institutions 14% non-convertible debentures worth Rs 10 crores. These debentures are redeemable in full at a premium of 5% on 25th June, 1996. 1990 - The Company commissioned a plant with an installed capacity of 500 tonnes per annum for the manufacture of pyridine and picoline. - The Company undertook to expand the production capacities of vinyl acetate monomer and its intermediaries i.e., acetic anhydride and acetic acid. The expanded capacities were commissioned in October 1990. - The Company privately placed 14% redeemable non-convertible debentures of Rs 100 each aggregating Rs 5.00 crores. These debentures are redeemable at a premium of 5% in three equal annual instalments commencing on 11th September, 1996. - During the year, another 5,00,000-14% redeemable non-convertible debentures of Rs 100 each were privately placed with a provision to redeem at a premium of 5% in three equal instalments commencing on 29th March, 1997. 1992 - Ramganga Fertilizers Ltd. (RFL) was amalgamated with the company effective 1st April, as per BIFR Scheme. As per the scheme of amalgamation 2,56,522 No. of equity shares of Rs 10 each were issued at par to the shareholders of erstwhile RFL in the ratio of one equity share of the company for every 10.35 No. of equity share of Rs 10 each fully paid-up of the erstwhile RFL. 1995 - A technical collaboration agreement was signed with Kemira Coatings Ltd., U.K., to manufacture wood finishes a polymer based product. Another agreement was also signed with M/s. Teutoburg, Germany to manufacture construction chemicals in its plant at Gajraula. - The company proposed to install an additional turbine generator with a capacity of 5.5 MW in view of high and frequently incidence of power failure and fluctuation. The company also proposed to increase the installed capacity of Pyridine & Picolines by 4,000 tonnes per annum to meet the increasing demand for the products. - 2,56,522 No. of equity shares issued to the shareholders of erstwhile RFL on merger of the said company with company. 1996 - The Company proposed to open offices in Singapore to cater to the need of S.E. Asia & China & European markets. With a view to tackling the power failure and fluctuations, the company proposed to instal a turbine generator with a capacity of 5.5 MW. - The company made a capital expenditure of Rs 26.40 crores for taking up projects such as Pyridene & Picolines, wood furnisher, construction chemicals with the intention of saving valuable foreign Exchange. It was also proposed to modernise its sulphuric acid plant. With a view to saving energy the company proposed to instal biogas fired boiler. 1997 - The Company faced a sharp decline in sales realisation of Acetic Acid and VAM, due to a combination of the South East Asian financial debacle and the large capacity build up of Acetic Acid and VAM in South Korean and Singapore. - The company has embarked on a substantial capital expenditure programme to enhance capacities of existing products and also manufacture new products. - Vam Organic Chemicals Ltd has registered a 8.97 per cent increase in net profit for the year ended March 31, 1997 at Rs.23.07 crores as compared to Rs.21.17 crores in the previous year. 1998 - Vam Organics Chemicals has introduced a specialist adhesive Vam Bond 2001. - The dry silica venture, jointly promoted by Vam Organics and Degussa AG of Germany with a 34 per cent stake each has not been doing too well. - The company's performance has been affected due to low international prices, steady increase in prices of major raw materials and sluggish growth in the overall market. - VAM Organic Chemicals Ltd (VOCL) proposes to merge group companies Anichem India Ltd (AIL) and Enpro Speciality Chemicals Ltd (ESCL) with itself. - A planned shut-down of the fertiliser plant was undertaken for 72 days in the quarter for revamping. It also increased its installed capacity from 125 tonnes per day to 175 tonnes per day for sulphuric acid. A captive power plant of 12.45 MW was commissioned in July this year. - VAM Organic Chemicals Ltd is exploring the possibility of entering into areas such as sugar, speciality chemicals and bulk drugs. - The non-convertible debenture programme of Vam Organic Chemicals Ltd has been downgraded by ICRA to LA- LAA-. Vam was the largest player in the alcohol-based organic chemical industry with the largest capacities in the country for most of its products including acetic acid, acetic anhydride, etc. 1999 - VAM Organic Chemicals Ltd (VOCL) has proposed to consolidate and improve its existing position in the chemical industry in the current fiscal. - VOCL has also commissioned the units of Polychem Ltd, manufacturing alcohol-based chemicals in May. - The Company's 22,500 tonnes per annum formaldehyde plant has been commissioned, permitting it to export greater quantities of picolines and pyridines. It has also installed new boilers and increased the capacities of existing plants. 2000 -Enters the Bio / chemo informatics arena by setting up Jubilant Biosys Ltd. 2001 -New corporate identity: Jubilant Organosys Ltd. reflecting changed corporate and business profile 2002 -Acquires the Active Pharmaceutical Ingredients business 2003 -Trading symbol of Jubilant Organosys Limited is changed from 'VAMORGANIC ' to 'JUBILANT' -Jubliant Securites Pvt. Ltd. & Jubliant Capital Pvt. Ltd has acquired 4,38,068 (2.99% of total paid up capital) equity shares. -Mr. H K Khan (Retd. IAS) has been appointed as additional director with effect from November 05, 2003 on the Board. 2004 -Jubilant Organosys Limited has informed that the Board of Directors at their meeting held on January 9, 2004 have approved for voluntary delisting of equity shares of the Company from The Delhi Stock Exchange Association Limited, The Calcutta Stock Exchange Association Limited, Kolkata and the Uttar Pradesh Stock Exchange Association Limited subject to the approval of shareholders by special resolution. -Jubilant Organosys acquires generic pharma Companies in Europe -Jubilant Organosys signs international contracts worth US$ 60 million in CRAMS for the year 2007 2005 -Acquired pharmaceutical company in USA involved in off patent drug development and supply, and owns US FDA approved manufacturing facility for solid dosage forms. -Acquires full service Clinical Research Organization in USA involved in providing clinical research services, data management, biostatistics and contract staffing. -Acquires Target Research Associates, Inc., renamed Clinsys Inc.; a US based Clinical Research Organisation (CRO) -Acquires Trinity Laboratories, Inc. and its wholly owned subsidiary, Trigen Laboratories, Inc., renamed Jubilant Pharmaceuticals, Inc., a generic pharmaceutical company in USA having a US FDA approved formulations manufacturing facility -Enters Clinsys Clinical Research Ltd. business by setting up wholly owned subsidiary Jubilant Clinsys Ltd. 2006 -Selected as one of the top 25 companies for Institute of Company Secretaries of India National Award for Excellence in Corporate Governance -Finalist in Golden Peacock Award for Excellence in Corporate Governance -Company has splits its Face value of Shares from Rs 5 to Re 1 2007 -Jubilant Organosys Ltd has acquired 100% equity stake in Hollister-Stier Laboratories LLC, USA, engaged in high growth Injectable contract manufacturing and well established and stable Allergy Immunotherapy businesses. -Acquires Hollister Stier Laboratories in USA, a contract manufacturer of Sterile injectable vials and allergenic extracts. 2008 -Acquires DRAXIS Specialty Pharmaceuticals, Inc. Canada, a contract manufacturer of sterile & non-sterile products and radiopharmaceuticals -Acquires Speciality Molecules Pvt. Ltd. Engaged in the manufacturing of Fine Chemicals used by Life Science Industry including pharma, agro & cosmetic industry. -Jubilant Organosys and Lilly form Drug development joint venture - Uttar Pradesh-based pharma major Jubilant Organosys Ltd (JOL) has secured new contracts worth $92 million (Rs.3.7 billion). The contracts have been signed under Customs Research and Manufacturing Services (CRAMS). Besides marketing its products in the regulated markets of the US, Europe and Japan, the company has managed to make forays into China, said a statement of JOL. 2009 -Jubilant enters into multiple Drug discovery partnerships with leading pharma and biotech -companies such as AstraZeneca, Orion, Endo pharmaceuticals & BioLeap and also extends its collaboration with Lilly for five years. -Jubilant enters into drug development collaborations with academia, University of Alabama at Birmingham and Southern Research Institute (USA) and Duke University (Singapore). -Jubilant Kalpataru - 120 bed super specialty hospital at Barasat, Kolkata, India inaugurated by Hon'ble Minister of Finance Shri Pranab Mukherjee 2010 -ET - IMEA 2009 Platinum Award by Frost & Sullivan, in the Pharmaceutical category for the API facility at Nanjangud -Best CFO (FMCG, Health and Retail Sector) to Mr. R. Sankaraiah by Institute of Chartered Accountants of India in January, 2010 - Jubilant Organosys Ltd has appointed Mr. Shardul S. Shroff as Additional Director of the Company with effect from March 15, 2010. - Jubilant Organosys Ltd has signed a USD 51 million CRAMS contract with a leading Life Sciences Company 2010 -The Company has changed from "Jubilant Organosys Ltd" to "JUBILANT LIFE SCIENCES LTD" -Mr. Shardul S. Shroff has been appointed as Additional Director of the Company. 2011 -Jubilant Life Sciences Ltd has announced another successful delivery of an early stage milestone in the Pain therapeutic area. -Jubilant Org - Jubilant sets up global scale capacities for Symtet - developed through 2012 -JubilantLife - announced today that they have achieved an early stage milestone in one of their collaborative programs with Chadds Ford. -"Jubilant HollisterStier Announces Multi-Million Dollar Award for the manufacture of Sterile Parenteral Products". -"Jubilant SEZ at Bharuch, inaugurated by Shri Narendra Modi, Hon'ble Chief Minister of Gujarat". 2013 - "Jubilant Life Sciences receives prestigious NDTV Profit Business Leadership Award 2012 for Corporate Social Responsibility." - Jubilant Life Sciences receives ANDA approval for Quetiapine Fumarate Tablet -Jubilant Life Sciences declared winner of Supply Chain Excellence Awards' at 7th Express, Logistics & Supply Chain Leadership Awards 2013 2014 - Jubilant Life Scienc - Results of Tender Offer for acquisition of minority shares of Cadista Holdings Inc. - Board recommended a Dividend of Rs.3 per equity shares of Rs.1 -Jubilant Life Sciences wins Excellence Awards at `India Pharma Awards' 2014 -Jubilant Life Sciences conferred with Golden Peacock Business Excellence Award-2014 2015 -Gold Award in Ankleshwar Chapter Convention on Quality Concepts 2015 (ACCQC) -Two Honors at the 10th Annual CIO100 Awards by CIO Magazine - CIO100 Innovation Architect Special Awards 2015 and Versatile 100honorees -Golden Peacock National Quality Award for Quality -Dataquest Business Technology Awards for Best IT Implementation in Analytics, Mobility, Cloud, ERP/CSM/CRM -ASSOCHAM's `Responsible Organization Excellence' Award 2014-15 -50 Most Talented Sustainability Leaders Award -15th Annual Greentech Environment Award 2014 - Gold Category winner under Chemicals and Pharmaceutical sector" - Gajraula plant, India -I.C.O.N.I.C IDC Insights Award, under `Health and Life Sciences vertical 2016 - Jubilant Life Sciences Limited won the Sustainability Award for Best Green Process in Chemical sector of FICCI Chemicals & Petrochemicals Awards, 2016. 2017 -Jubilant gets USFDA nod for generic anti-fungal capsules. -Jubilant Life eyes speciality pharma biz acquisition in US. -Jubilant completes acquisition of Radiopharmacy business of Triad. -"Second Awards" under the category of Basic Inorganic, Organic Chemicals including Agro Chemicals for the outstanding export performance of the year 2015-16 by CHEMEXCIL. -'Most Consistent IR (Investor Relations) Practice in the country' Award for the year 2017 instituted by IR Society of India -Green tech Environment Award 2017 received by Nanjangud Plant Jubilant Life Sciences Ltd, Gajraula awarded with CII 17th National -Award for Excellence in Energy Award 2016 In Category of Chemical/Pharma/Fertilizers.
Alankit Assignment Ltd.